Collegium Pharmaceutical Inc (NASDAQ:COLL) reported its fourth quarter and full-year 2025 financial results, delivering a quarter of solid revenue growth that met Wall Street's expectations but falling short on profitability. The market's initial reaction, reflected in pre-market trading, was negative as investors digested the earnings miss and the company's forward guidance.
Quarterly Performance Versus Estimates
The company's top-line performance for the quarter ended December 31, 2025, was robust, continuing a trend of double-digit growth. However, a closer look at the figures against analyst forecasts reveals a mixed picture.
- Revenue: Collegium reported Q4 net product revenues of $205.4 million, a 13% increase year-over-year. This result was essentially in line with analyst estimates, which had anticipated approximately $210.5 million.
- Earnings Per Share (Non-GAAP): The company reported adjusted earnings per share (EPS) of $2.04. This fell short of the consensus analyst estimate of $2.37, representing a miss of approximately 14%.
The divergence between revenue and earnings performance suggests margin pressures or higher-than-anticipated expenses during the quarter. While the company successfully grew its sales, it was unable to translate that growth into expected levels of profitability, which appears to be the primary driver behind the negative market sentiment.
Full-Year Results and 2026 Guidance
For the full year 2025, Collegium posted record net revenues of $780.6 million, a significant 24% increase over the prior year. Adjusted EBITDA also reached a record $460.5 million, up 15% year-over-year. The company's performance was heavily driven by its ADHD drug, Jornay PM®, which saw net revenue soar 48% for the year to $148.9 million.
Looking ahead, management reaffirmed its financial guidance for 2026. This outlook can be directly compared to existing analyst consensus estimates.
- Collegium's 2026 Revenue Guidance: $805 to $825 million (midpoint: $815 million)
- Analyst Consensus Estimate for 2026 Revenue: Approximately $825.7 million
The company's guidance midpoint sits about 1.3% below the current analyst consensus. For the first quarter of 2026, the gap is more pronounced; Collegium's implied trajectory based on full-year guidance suggests a Q1 figure that may be below the analyst estimate of $198.6 million. This conservative outlook, particularly when juxtaposed with the recent EPS miss, likely contributed to the cautious investor reaction.
Business Highlights and Strategic Position
Beyond the headline numbers, the earnings release underscored several key strengths in Collegium's business model:
- Jornay PM as a Growth Engine: The ADHD treatment continues to demonstrate exceptional growth, with quarterly revenue up 57% year-over-year to $45.9 million. Prescriptions and prescribers reached all-time highs, validating the company's commercial execution.
- Durable Pain Portfolio: The established pain franchise, including Belbuca and Xtampza ER, delivered stable performance with full-year net revenues up 6% to $631.7 million, providing a steady cash flow base.
- Strengthened Balance Sheet: The company ended the year with $386.7 million in cash and marketable securities after generating strong operating cash flow. It also successfully refinanced its debt in December, securing a new $980 million credit facility expected to yield meaningful interest savings and provide flexibility for potential business development.
Market Reaction and Investor Takeaway
The pre-market decline of nearly 3% following the earnings release is a clear signal that the market is penalizing the earnings miss and the guidance that appears cautious relative to expectations. While Collegium's underlying business shows strong growth, particularly in its key product line, the quarter highlighted challenges in bottom-line conversion.
Investors will likely focus on the company's ability to manage expenses and improve profitability margins in the coming quarters while maintaining the impressive growth trajectory of Jornay PM. The upcoming series of investor conferences in March 2026 will offer management a platform to address these concerns and provide further color on their growth strategy and capital deployment plans.
For a detailed look at historical earnings and future analyst estimates for Collegium Pharmaceutical, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy, sell, or hold any security. The information presented is based on publicly available sources and should not be the sole basis for making any investment decisions.